ReviewEuropean journal of immunology2025
Beyond Negative Regulation: IL-1R8 and IL-1R2 as Novel Immune Checkpoints.
Review in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026Review
- Beyond Negative Regulation: IL-1R8 and IL-1R2 as Novel Immune Checkpoints.European journal of immunology · 2025Review
- Structural and dynamic properties of IL1 receptors.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
IL-1 family members and their signaling receptors are key drivers of inflammation in sterile or infectious conditions, as well as polarization of the innate and adaptive immunity. Deregulated or excessive activation of the IL-1 system is associated with detrimental inflammatory reactions. Beside signaling receptors, IL-1-family receptors comprise decoy or negative regulatory receptors, which regulate cell activation mediated by IL-1 family ligands. IL-1-family negative regulatory receptors, which include IL-1R8 and IL-1R2, have peculiar structural features and functions essential to the self-regulation of the IL-1 system. IL-1R8 and IL-1R2 emerge as regulatory molecules whose function is context-dependent, spanning from negative regulation of inflammation in infections or conditions of sterile inflammation and cell damage, including cancer-related inflammation, to skewing of myeloid and lymphoid cells, modulation of anti-tumor immunity, and immune checkpoint activity. This review reports new insights into the physio-pathological roles of these two negative regulatory IL-1 family members, emphasizing their mechanisms of action and potential for innovative therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.